DaBomb Protein Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	107.03	132.17	253.59	379.99	195.18	197.14
Trading Asset Securities	-	-	-	0.08	-	-
Cash & Short-Term Investments	135.88	132.17	253.59	380.07	195.18	197.14
Cash Growth	-43.31%	-47.88%	-33.28%	94.73%	-0.99%	-25.78%
Accounts Receivable	47.51	39.97	32.28	51.25	36.99	56.04
Other Receivables	2.13	2.12	2.76	1.08	1.44	1.07
Receivables	49.64	42.09	35.05	52.34	38.42	57.11
Inventory	25.58	19.05	34.07	20.23	52.79	37.68
Prepaid Expenses	4.83	3.9	3.87	4.89	19.54	39.97
Other Current Assets	-	28.47	327.59	321.31	36.84	69.73
Total Current Assets	215.93	225.68	654.16	778.83	342.76	401.62
Property, Plant & Equipment	832.29	832.71	621.59	564.83	888.09	876.14
Long-Term Investments	-	-	-	-	0.18	0.04
Other Intangible Assets	0.18	0.19	0.21	0.19	0.28	0.37
Long-Term Deferred Tax Assets	7.79	7.29	8.55	12.31	13.85	9.2
Other Long-Term Assets	29.26	29.9	30.76	45.74	34.92	49.12
Total Assets	1,085	1,096	1,315	1,402	1,280	1,336
Accounts Payable	19.52	12.59	13.9	9.14	28.5	10.47
Accrued Expenses	-	7.33	12.88	11.05	11.8	17.22
Short-Term Debt	8	28	90	92	95	161
Current Portion of Long-Term Debt	-	26.18	30.98	238.29	66.66	18.47
Current Portion of Leases	0.47	0.52	1.14	0.98	1.37	1.51
Current Unearned Revenue	0.86	0.03	-	0.23	2.4	-
Other Current Liabilities	40.43	9.84	30.09	5.08	12.64	13.86
Total Current Liabilities	69.28	84.49	178.98	356.77	218.37	222.53
Long-Term Debt	14.58	19.43	45.41	85.7	330.94	433.22
Long-Term Leases	-	0.09	0.6	0.63	1.61	3.81
Long-Term Unearned Revenue	-	-	0.22	0.65	1.42	2.41
Long-Term Deferred Tax Liabilities	3.08	2.48	0.75	0.08	0.55	0.28
Total Liabilities	86.94	106.48	225.96	443.83	552.88	662.24
Common Stock	719.42	719.42	679.86	597.1	395.14	330.82
Additional Paid-In Capital	338.7	338.7	355.25	344.46	286.31	246.9
Retained Earnings	-49.7	-55.26	26.31	4.3	61.32	105.98
Comprehensive Income & Other	-9.92	-13.59	27.89	12.21	-15.56	-9.46
Shareholders' Equity	998.49	989.28	1,089	958.06	727.2	674.24
Total Liabilities & Equity	1,085	1,096	1,315	1,402	1,280	1,336
Total Debt	23.06	74.21	168.13	417.6	495.59	618.01
Net Cash (Debt)	112.82	57.96	85.45	-37.53	-300.41	-420.87
Net Cash Growth	40.09%	-32.18%	-	-	-	-
Net Cash Per Share	1.57	0.81	1.19	-0.70	-7.76	-12.96
Filing Date Shares Outstanding	71.94	71.94	67.99	59.71	39.51	33.08
Total Common Shares Outstanding	71.94	71.94	67.99	59.71	39.51	33.08
Working Capital	146.65	141.19	475.19	422.07	124.39	179.09
Book Value Per Share	13.88	13.75	16.02	16.05	18.40	20.38
Tangible Book Value	998.31	989.09	1,089	957.88	726.92	673.88
Tangible Book Value Per Share	13.88	13.75	16.02	16.04	18.40	20.37
Land	-	401.07	401.07	401.07	401.07	400.92
Buildings	-	313.83	138.81	133.06	320.83	317.42
Machinery	-	304.77	187.52	177.46	291.48	256.69
Construction In Progress	-	1.56	51.76	-	0.24	1.42
Leasehold Improvements	-	51.75	25.83	25.31	54.72	53.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.